PROM1 and prostate carcinoma: To test our hypothesis, the expression of CD133 and CD44 was first analyzed on tissue microarrays from prostate cancer patients since prostate cancer expressing both CD133 and CD44 represent a rare population of cells with stem cell-like properties [15].